Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices

Biosimilars are highly similar but nonidentical biologic agents with no differences in clinical efficacy and safety when compared to bio-originator products. Considering the long-term costs of managing inflammatory bowel disease (IBD), biosimilars, through economic competition, provide an opportunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat, Shubha, Qazi, Taha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802378/
https://www.ncbi.nlm.nih.gov/pubmed/36777069
http://dx.doi.org/10.1093/crocol/otaa093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802378/
https://www.ncbi.nlm.nih.gov/pubmed/36777069
http://dx.doi.org/10.1093/crocol/otaa093

Ejemplares similares